Inpart is the leading platform for scientific partnering. We provide comprehensive solutions to initiate, optimize, and manage collaborations across industry and academia. In 2022, market-leading biopharma partnering platform Inova successfully merged with IN-PART, a specialized online matchmaking platform focused on fostering collaboration between academia and industry. The strategic union of the two companies as Inpart now offers a powerful platform equipping teams across pharma,biotech, and academia with solutions toshowcaseinnovations and technologies;finduntapped science;identifynew partners;acceleratedeal-making; andmanagecollaborations. Our commitment to excellence, creativity, and purpose-driven initiatives fuels our mission to connect the right partners at the righttime for the purpose ofbringingscience to the marketfaster.
| Website | https://inpart.io |
| Revenue | $5.5 million |
| Employees | 180 (110 on RocketReach) |
| Founded | 2014 |
| Industry | Technology, Information and Internet |
| Keywords | Research Collaboration Platform, Innovation Platform, Research Partnerships, Collaboration Software, Technology Transfer, Biotech Partnerships, Open Innovation, Research Management, Drug Discovery, Technology Licensing, Life Sciences, Clinical Trials, Pharmaceutical Collaborations, Global Partnerships, Deal Management |
| Competitors | Y Combinator, Techstars, AngelList, Funding Circle UK, Crowdcube, Seedrs, Seedcamp, Crowdfunder UK, GrantTree, EquityNet +31 more (view full list) |
Looking for a particular Inpart employee's phone or email?
The Inpart annual revenue was $5.5 million in 2026.
Gilles Toulemonde is the CEO, co-founder of Inpart.
110 people are employed at Inpart.